Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Psyence Biomedical Ltd. Warrant (PBMWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: PBMWW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.15 | 52 Weeks Range 0.00 - 0.05 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.2% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 71171 |
Shares Outstanding - | Shares Floating 71171 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Psyence Biomedical Ltd. Warrant
Company Overview
History and Background
Psyence Biomedical Ltd. is a life sciences company focused on the research, development, and commercialization of psilocybin-based therapeutics. The company's warrants represent a right to purchase shares of Psyence Biomedical Ltd. at a specified price within a certain timeframe. Significant milestones include the establishment of clinical trials and partnerships for the development of mental health treatments. The evolution of the company is tied to the growing acceptance and scientific exploration of psychedelic compounds for therapeutic purposes.
Core Business Areas
- Psilocybin Therapeutics: Development of pharmaceutical-grade psilocybin for clinical applications in treating conditions like depression, anxiety, and PTSD.
- Clinical Research and Development: Conducting rigorous clinical trials to demonstrate the safety and efficacy of psilocybin-based treatments.
- Commercialization and Distribution: Establishing pathways for the eventual commercialization and distribution of approved psilocybin therapies.
Leadership and Structure
Psyence Biomedical Ltd. is led by a management team with expertise in pharmaceuticals, biotechnology, and clinical research. The organizational structure is typical of a biotech company, with departments dedicated to R&D, regulatory affairs, clinical operations, and business development. Specific leadership details would require accessing current company filings.
Top Products and Market Share
Key Offerings
- Psilocybin-Based Therapeutics (Pipeline): Psyence Biomedical Ltd. is developing a pipeline of psilocybin-based therapeutics. Specific products are in various stages of clinical development. Market share is currently negligible as these are investigational products. Competitors include companies like Compass Pathways, MindMed, and ATAI Life Sciences, who are also developing psychedelic therapeutics.
Market Dynamics
Industry Overview
The psychedelic therapeutics market is a nascent but rapidly growing sector within the pharmaceutical industry. It is driven by increasing scientific evidence supporting the efficacy of psychedelics for various mental health conditions and a growing demand for novel treatment options. Regulatory landscapes are evolving, with some jurisdictions moving towards decriminalization and medical access.
Positioning
Psyence Biomedical Ltd. is positioned as an early-stage player in the psychedelic therapeutics market, focusing on rigorous scientific research and clinical validation. Its competitive advantage lies in its commitment to developing pharmaceutical-grade psilocybin and conducting comprehensive clinical trials.
Total Addressable Market (TAM)
The TAM for mental health therapeutics is vast, estimated in the hundreds of billions of dollars globally. The specific TAM for psilocybin-based therapeutics is still being defined as the market matures and regulatory approvals are granted. Psyence Biomedical Ltd. aims to capture a significant portion of this emerging market by addressing unmet needs in mental healthcare.
Upturn SWOT Analysis
Strengths
- Focus on pharmaceutical-grade psilocybin production.
- Commitment to rigorous clinical trial design.
- Experienced leadership team in biotech.
- Potential first-mover advantage in specific therapeutic areas.
Weaknesses
- Early-stage development with no approved products yet.
- High R&D costs and long development timelines.
- Dependence on regulatory approval.
- Limited brand recognition compared to established pharmaceutical giants.
Opportunities
- Growing acceptance and de-stigmatization of psychedelics for mental health.
- Unmet needs in treating prevalent mental health disorders.
- Potential for strategic partnerships and collaborations.
- Expansion into international markets.
Threats
- Strict and evolving regulatory hurdles.
- Competition from other psychedelic therapy developers.
- Potential for public perception backlash or negative trial outcomes.
- Financing risks inherent in early-stage biotech.
Competitors and Market Share
Key Competitors
- Compass Pathways plc (CMPS)
- Mind Medicine (MindMed) Inc. (MNMD)
- atai Life Sciences N.V. (ATAI)
Competitive Landscape
Psyence Biomedical Ltd. faces intense competition from other companies in the psychedelic therapeutics space. Its advantages lie in its scientific focus and potential for niche therapeutic applications. Disadvantages include its smaller size and earlier stage of development compared to some competitors who may have more advanced clinical programs or greater access to capital.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Psyence Biomedical Ltd. has been characterized by organizational development, progression of its scientific research, and securing funding to advance its pipeline.
Future Projections: Future growth projections are contingent on the successful outcomes of clinical trials, regulatory approvals, and effective commercialization strategies. Analyst estimates, if available, would reflect these potential future developments.
Recent Initiatives: Recent initiatives would likely include the initiation or advancement of clinical trials, formation of strategic partnerships, and efforts to secure further funding.
Summary
Psyence Biomedical Ltd. is a promising early-stage company in the burgeoning psychedelic therapeutics market. Its strengths lie in its scientific rigor and focus on pharmaceutical-grade psilocybin. However, it faces significant risks associated with lengthy R&D, regulatory hurdles, and intense competition. The success of its future hinges on the outcomes of its clinical trials and its ability to navigate the evolving regulatory landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (hypothetical, as specific warrant data is proprietary)
- Industry research reports on psychedelic therapeutics
- Financial news outlets
Disclaimers:
This JSON output is based on general knowledge of Psyence Biomedical Ltd. and the psychedelic therapeutics market. Specific details regarding the Psyence Biomedical Ltd. Warrant (e.g., strike price, expiration date, number of outstanding warrants) are not publicly available without accessing specific financial filings or prospectuses and are therefore not included. This analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Warrant
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-26 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.psyencebiomed.com |
Full time employees 12 | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.